Anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration
OwnerRenata Pasqualini, Wadih Arapinventors
Life of this patent
Estimating the term…
Loading patent…
OwnerRenata Pasqualini, Wadih Arapinventors
Estimating the term…
Neonatal mice with classic inherited retinal degeneration (Pdebrd1/Pdebrd1) are disclosed which fail to mount reactive retinal neovascularization in a mouse model of oxygen-induced proliferative retinopathy. Also disclosed is a comparable human paradigm: spontaneous regression of retinal neovascularization associated with long-standing diabetes mellitus which occurs when retinitis pigmentosa becomes clinically evident. Both mouse and human data indicate that reactive retinal neovascularization either fails to develop or regresses when the number of photoreceptor cells is markedly reduced. The results show that a functional mechanism underlying this anti-angiogenic state is failure of the predicted up-regulation of vascular endothelial growth factor (VEGF), although other growth factors may also be involved. Preventive and therapeutic methods useful against both proliferative and degenerative retinopathies are also disclosed.
A method of reducing and/or preventing retinopathy of prematurity comprising:
A method of reducing and/or preventing diabetic retinopathy comprising:
A method of identifying inhibitors of retinal neovascularization comprising:
A method of preventing retinal neovascularization comprising:
A pharmaceutical composition comprising an inhibitor of rod cell oxidative metabolism.
Dependencies are inferred from the claim text.